cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.21435132
title: The Data of 'UAV Remote Sensing Monitoring of Yellow Leaf Disease of Arecanut'

description: The areca industry is one of the main sources of income in the Hainan Province of China, accounting for the income of nearly 2.3 million farmers. The areca yellowing disease is a highly infectious disease that has severely deteriorated the production and cultivation of areca. We did a study to apply the multispectral data obtained by using a UAV along with highresolution UAV remote sensing images to monitor the severity of the areca yellowing disease through five machine learning algorithms. The following is the data package of our research: 1.The data in the folder (Areca Vegetation Index) is the vegetation index calculated by the DJI Phantom 4 RTK to obtain the multi-spectral image and then import it into the DJI Terra software through the two-dimensional multi-spectral reconstruction. 2.The data in the folder (Machine Learning Classification) contains the vegetation index data of 200 sampling points of 603 areca trees, the vegetation index data of 57 areca trees and the identification results of the yellowing area, and the yellowing prediction training set of five machine learning methods and the predicted result. 3.The data in the folder (Model Accuracy Analysis) is the accuracy evaluation result of the correlation model between the LVV of areca and the severity of the Yellow Leaf Disease of Arecanut. 4.The data in the folder (The Severity of the Yellow Leaf Disease of Arecanut and LVV) is the prediction results of the severity of the yellow leaf disease of arecanut and the LVV measurement results of 603 areca trees in the research area. 5.The data in the folder (The Research Area DOM) is a digital orthophoto map of the research area. 6.The data in the folder (3D Point Cloud of the Areca(LAS)) is the 3D point cloud data of the research area, which is in LAS format. 7.The data in the folder (Figures) is the relevant illustration in the research paper.
DOI: 10.5281/zenodo.7266718
title: Observing the quantum topology of light

description: Includes all experimental data and simulation data in the manuscript "Observing the quantum topology of light"
DOI: 10.5281/zenodo.7266717
title: Observing the quantum topology of light

description: Includes all experimental data and simulation data in the manuscript "Observing the quantum topology of light"
DOI: 10.6084/m9.figshare.21369855
title: Supplementary Material - Ecological networks of an Antarctic ecosystem: a full description of non-trophic interactions

description: Data of non-trophic interactions of Potter Cove marine ecosystem and bibliography searching process.
DOI: 10.6084/m9.figshare.21369855.v2
title: Supplementary Material - Ecological networks of an Antarctic ecosystem: a full description of non-trophic interactions

description: Data of non-trophic interactions of Potter Cove marine ecosystem and bibliography searching process.
DOI: 10.5281/zenodo.7266722
title: Manganese Limitation of Phytoplankton Physiology and Productivity in the Southern Ocean

description: Output to accompany: Manganese Limitation of Phytoplankton Physiology and Productivity in the Southern Ocean Nicholas J. Hawco*, Alessandro Tagliabue*, Benjamin S. Twining * joint first authors First published: 25 October 2022 https://doi.org/10.1029/2022GB007382 Netcdf file details:<br> <br> BYONIC8R1 = standard run<br> !<br> BYONIC6R1 = as BYONIC8R1 but no zn-mn interaction<br> BYONIC3R1 = as BYONIC8R1 but no Mn limitation<br> BYONIC7R1 = as BYONIC8R1 but lower mnchl<br> BYONIC2R1 = as BYONIC8R1 but higher mnchl<br> BYONIC5R1 = as BYONIC8R1 but w/ QZn feedback<br> BYONIC12R1 = BYONIC8R1 LGM<br> BYONIC10R1 = no Mn lim LGM All on native ORCA2 NEMO grid
DOI: 10.5281/zenodo.7266721
title: Manganese Limitation of Phytoplankton Physiology and Productivity in the Southern Ocean

description: Output to accompany: Manganese Limitation of Phytoplankton Physiology and Productivity in the Southern Ocean Nicholas J. Hawco*, Alessandro Tagliabue*, Benjamin S. Twining * joint first authors First published: 25 October 2022 https://doi.org/10.1029/2022GB007382 Netcdf file details:<br> <br> BYONIC8R1 = standard run<br> !<br> BYONIC6R1 = as BYONIC8R1 but no zn-mn interaction<br> BYONIC3R1 = as BYONIC8R1 but no Mn limitation<br> BYONIC7R1 = as BYONIC8R1 but lower mnchl<br> BYONIC2R1 = as BYONIC8R1 but higher mnchl<br> BYONIC5R1 = as BYONIC8R1 but w/ QZn feedback<br> BYONIC12R1 = BYONIC8R1 LGM<br> BYONIC10R1 = no Mn lim LGM All on native ORCA2 NEMO grid
DOI: 10.6084/m9.figshare.21378321
title: Supplementary Material for: Risk Factors of Postoperative Intra-Abdominal Infectious Complications After Robotic Gastrectomy for Gastric Cancer

description: Introduction: Robotic surgery is regarded as an evolved type of laparoscopic surgery. Few studies have undertaken detailed analysis of complications following robotic gastrectomy for gastric cancer. Methods: This is a single-center retrospective study of 149 consecutive patients with gastric cancer who underwent robotic gastrectomy. It examines in detail the postoperative complications in robotic gastrectomy for gastric cancer, focusing on intra-abdominal infectious complications including anastomotic leakage, pancreatic fistula and intra-abdominal abscess. We also aim to identify the related risk factors. Results: The median operation time was 299 min and median bleeding was 25 ml. The incidence of overall complications higher than grade II was 8.7%. Clinically serious complications higher than grade IIIa occurred in 6.7% of cases. The incidence of intra-abdominal infectious complications that were higher than grade II was 4.0%. Mortality in our consecutive series was zero. Multivariate logistic regression analysis indicated that postoperative intra-abdominal infectious complications were significantly associated with history of abdominal surgery (P = 0.043), with odds ratios of 17.890 (95 % confidence interval 1.092 – 293.150) and with non-curative resection (P = 0.025), with odds ratios of 58.629 (95 % confidence interval 1.687 – 2037.450). Discussion/Conclusion: Robotic gastrectomy was shown to be a safe and effective treatment for gastric cancer when performed by experienced surgeons. Attention should be paid to the risk of developing postoperative complications when performing robotic gastrectomy in gastric cancer patients with a history of abdominal surgery and in patients with advanced gastric cancer in whom there is expected to be difficulty in curative resection.
DOI: 10.6084/m9.figshare.21435789
title: GSM3262860_human_sperm_atacseq_Nuc.bw

description: <strong>GSM3262860_human_sperm_atacseq_Nuc.bw</strong>
DOI: 10.6084/m9.figshare.21435789.v1
title: GSM3262860_human_sperm_atacseq_Nuc.bw

description: <strong>GSM3262860_human_sperm_atacseq_Nuc.bw</strong>
DOI: 10.6084/m9.figshare.21435615.v1
title: Supplementary Material for: Treatment Delays and Chance of Reperfusion Therapy in Patients with Acute Stroke: A Danish Nationwide Study

description: <b><i>Introduction:</i></b> We aimed to determine the treatment delay for ischemic stroke patients in Denmark. <b><i>Methods:</i></b> A nationwide register-based study on acute ischemic stroke patients admitted through emergency medical services. Treatment delay comprised patient, prehospital, and in-hospital delay. Analyses were stratified according to length of prehospital delay (&lt;3 vs. ≥3 h). <b><i>Results:</i></b> A total of 5,356 ischemic stroke episodes were included. The median onset-to-door time was 187 min, and 2,405 (43%) arrived at the stroke unit within 3 h. Overall, the median patient delay was 115 min. For early arrival (<i>n</i> = 2,280), patient delay was 27 min compared to 437 min for late arrivals (<i>n</i> = 2,448). Median prehospital delay varied by 9 min between early- and late-arriving patients. Approximately 48% of the early-arriving patients compared to 9% of the late-arriving patients received i.v. thrombolysis. For thrombectomy, the numbers were 10% and 3%, respectively. This corresponded to an unadjusted relative risk (RR) of 0.18 (95% CI: 0.16–0.21) and adjusted (age, sex, cohabitation status, and stroke severity) RR of 0.20 (95% CI: 0.18–0.23) for i.v. thrombolysis when comparing patients arriving later than 3 h with patients arriving earlier. For thrombectomy, the unadjusted and adjusted RRs were 0.30 (95% CI: 0.23–0.39) and 0.40 (95% CI: 0.31–0.52), respectively. <b><i>Conclusions:</i></b> Patient delay remains the most important barrier for use of reperfusion therapy among acute ischemic stroke patients calling 1-1-2, whereas system delay seems independent of patient delay.
DOI: 10.6084/m9.figshare.21435600.v1
title: Supplementary Material for: Association between Extracranial Carotid Artery Plaque and Cognitive Dysfunction: A Systematic Review and Meta-Analysis

description: <b><i>Background:</i></b> Extracranial carotid atherosclerosis has been variably associated with dementia. Prior studies have focused on the association of carotid intima media thickness or carotid stenosis; however, there is evidence that carotid plaque may contribute to dementia, perhaps via microembolic phenomena. <b><i>Objectives:</i></b> We sought to evaluate the role of carotid plaque in contributing to cognitive impairment by performing a systematic review and meta-analysis to summarize the association between extracranial carotid plaque and cognitive dysfunction and dementia. <b><i>Methods:</i></b> We performed a comprehensive literature search evaluating the association of extracranial carotid plaque with cognition. We included studies measuring carotid plaque on ultrasound, computed tomography, or MR and also evaluated cognition through neuropsychological testing. Meta-analyses with assessment of study heterogeneity and publication bias were performed. Results were presented in a forest plot and summarized using a random-effects model. <b><i>Results:</i></b> After screening 1,674 studies, we included 40 for systematic review and 16 and 7 studies for two meta-analyses with a total of 19,029 and 27,325 patients, respectively. We found a positive relationship between the presence of extracranial carotid plaque and cognitive dysfunction with a pooled random-effects odds ratio (OR) of 1.83 (95% CI, 1.50, 2.24) and a pooled random-effects hazard ratio (HR) of 1.47 (95% CI, 1.15, 1.89), respectively. A sensitivity analysis of only longitudinal studies found a persistent positive association. Measures of heterogeneity showed moderate heterogeneity in each meta-analysis, respectively (I-squared statistic = 57% and 70%). <b><i>Conclusion:</i></b> The presence of extracranial carotid plaque is significantly associated with cognitive dysfunction and dementia in both cross-sectional and longitudinal analyses. After further confirmation, our results support carotid plaque being a potentially modifiable risk factor in the development of dementia.
DOI: 10.6084/m9.figshare.21435822
title: Supplementary Material for: Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment

description: Introduction: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus bevacizumab, resulting in a poor prognosis. Thus, the prediction and early detection of HCC is crucial. Methods: Patients with unresectable HCC treated with atezolizumab plus bevacizumab and had baseline preserved serum (n = 68) were screened and classified according to their PD, six weeks after treatment initiation (early PD; n = 13). Of these, four patients each with and without early PD were selected for cytokine array and genetic analyses. The identified factors were validated in the validated cohort (n = 60) and evaluated in patients treated with lenvatinib. Results: No significant differences were observed in the genetic alterations in circulating tumor DNA. Cytokine array data revealed that baseline MIG (CXCL9), ENA-78, and RANTES differed substantially between patients with and without early PD. Subsequent analysis in the validation cohort revealed that baseline CXCL9 was significantly lower in patients with early PD than that in patients without early PD, and the best cut-off value of serum CXCL9 to predict early PD was 333 pg/mL (sensitivity: 0.600, specificity: 0.923, AUC = 0.75). In patients with lower serum CXCL9 (&lt; 333 pg/mL), 35.3% (12/34) experienced early PD with atezolizumab plus bevacizumab, while progression-free survival (PFS) was significantly shorter relative to that in patients without (median PFS, 126 days vs 227 days; HR: 2.41, 95% CI: 1.22–4.80, p = 0.0084). While patients with objective response to lenvatinib had significantly lower CXCL9 levels compared with those of patients without. Conclusion: Baseline low serum CXCL9 (&lt; 333 pg/mL) levels may predict early PD in patients with unresectable HCC treated with atezolizumab plus bevacizumab.
DOI: 10.6084/m9.figshare.21435825
title: Supplementary Material for: Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment

description: Introduction: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus bevacizumab, resulting in a poor prognosis. Thus, the prediction and early detection of HCC is crucial. Methods: Patients with unresectable HCC treated with atezolizumab plus bevacizumab and had baseline preserved serum (n = 68) were screened and classified according to their PD, six weeks after treatment initiation (early PD; n = 13). Of these, four patients each with and without early PD were selected for cytokine array and genetic analyses. The identified factors were validated in the validated cohort (n = 60) and evaluated in patients treated with lenvatinib. Results: No significant differences were observed in the genetic alterations in circulating tumor DNA. Cytokine array data revealed that baseline MIG (CXCL9), ENA-78, and RANTES differed substantially between patients with and without early PD. Subsequent analysis in the validation cohort revealed that baseline CXCL9 was significantly lower in patients with early PD than that in patients without early PD, and the best cut-off value of serum CXCL9 to predict early PD was 333 pg/mL (sensitivity: 0.600, specificity: 0.923, AUC = 0.75). In patients with lower serum CXCL9 (&lt; 333 pg/mL), 35.3% (12/34) experienced early PD with atezolizumab plus bevacizumab, while progression-free survival (PFS) was significantly shorter relative to that in patients without (median PFS, 126 days vs 227 days; HR: 2.41, 95% CI: 1.22–4.80, p = 0.0084). While patients with objective response to lenvatinib had significantly lower CXCL9 levels compared with those of patients without. Conclusion: Baseline low serum CXCL9 (&lt; 333 pg/mL) levels may predict early PD in patients with unresectable HCC treated with atezolizumab plus bevacizumab.
DOI: 10.6084/m9.figshare.21435825.v1
title: Supplementary Material for: Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment

description: Introduction: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus bevacizumab, resulting in a poor prognosis. Thus, the prediction and early detection of HCC is crucial. Methods: Patients with unresectable HCC treated with atezolizumab plus bevacizumab and had baseline preserved serum (n = 68) were screened and classified according to their PD, six weeks after treatment initiation (early PD; n = 13). Of these, four patients each with and without early PD were selected for cytokine array and genetic analyses. The identified factors were validated in the validated cohort (n = 60) and evaluated in patients treated with lenvatinib. Results: No significant differences were observed in the genetic alterations in circulating tumor DNA. Cytokine array data revealed that baseline MIG (CXCL9), ENA-78, and RANTES differed substantially between patients with and without early PD. Subsequent analysis in the validation cohort revealed that baseline CXCL9 was significantly lower in patients with early PD than that in patients without early PD, and the best cut-off value of serum CXCL9 to predict early PD was 333 pg/mL (sensitivity: 0.600, specificity: 0.923, AUC = 0.75). In patients with lower serum CXCL9 (&lt; 333 pg/mL), 35.3% (12/34) experienced early PD with atezolizumab plus bevacizumab, while progression-free survival (PFS) was significantly shorter relative to that in patients without (median PFS, 126 days vs 227 days; HR: 2.41, 95% CI: 1.22–4.80, p = 0.0084). While patients with objective response to lenvatinib had significantly lower CXCL9 levels compared with those of patients without. Conclusion: Baseline low serum CXCL9 (&lt; 333 pg/mL) levels may predict early PD in patients with unresectable HCC treated with atezolizumab plus bevacizumab.
DOI: 10.23729/01909e60-d465-4e07-bace-763ce9f854e1
title: Hungarian Soil

description: The samples represent the B accumulation and E eluviation horizons of a Luvisol (brown forest soil) from Hungary. B horizon sample with thin clay accumulation layers, and iron rich coatings, layers. The E horizon does not show these features. Preview dataset found at https://doi.org/10.23729/bbf3a773-7e76-4c7d-a458-920c4fdeabd7 . To obtain data, please contact fairdata-pas@gtk.fi .
DOI: 10.2906/106117115116/2
title: 2020 Study on child participation on EU political and democratic life

description: In 2020, the European Commission commissioned a study on child participation in EU political and democratic life. The report covers 27 Member States and the UK, looking the child participation at the national level. For 10 countries, the researchers looked also at the local level. The report shows as well 12 case studies. More than 200 children and young people shared their opinions and experiences in interviews and focus groups that were organised.
DOI: 10.2906/112117098108/11
title: CORDIS - EU research projects under FP7 (2007-2013)
DOI: 10.2906/112117098108/12
title: CORDIS - EU research projects under Horizon 2020 (2014-2020)

description: This dataset contains information about projects and their results funded by the European Union under the Horizon 2020 framework programme for research and innovation from 2014 to 2020. The dataset is composed of six (6) different sub-set (in different formats): H2020 projects – which includes participating organisations, legal basis information, topic information, project URLs and classification with the European Science Vocabulary (EuroSciVoc) H2020 project IPRs (Intellectual Property Rights) H2020 project deliverables (meta-data and links to deliverables included since May 2019) H2020 project publications (meta-data and links to publications included since May 2019) H2020 report summaries (periodic or final publishable summaries included since September 2018) Principal Investigators in Horizon 2020 ERC projects Reference data (programmes, topics, topic keywords funding schemes (types of action), organisation types and countries) can be found in this dataset: https://data.europa.eu
DOI: 10.2906/112117098108/13
title: CORDIS - EU research projects under FP6 (2002-2006)

description: This dataset contains all projects funded by the European Union under the sixth framework programme for research and technological development (FP6) from 2002 to 2006. The file 'FP6 Projects' contains the public grant information for each project, including the following information: Record Control Number (RCN), project ID (grant agreement number), project acronym, project status, funding programme, topic, project title, project start date, project end date, project objective, project total cost, EC max contribution (commitment), call ID, funding scheme (type of action), coordinator, coordinator country, participants (ordered in a semi-colon separated list), participant countries (ordered in a semi-colon separated list). The participating organisations are listed in the file 'FP6 Organisations' which includes: project Record Control Number (RCN), project ID, project acronym, organisation role, organisation ID, organisation name, organisation short name, organisation type, participati
DOI: 10.2906/112117098108/14
title: CORDIS - EU funded projects under FP2 (1987–1991)

description: This dataset contains projects funded by the European Union under the second framework programme for research and technological development (FP2) from 1987 to 1991. The file 'FP2 Projects' contains the public grant information for each project, including the following information: Record Control Number (RCN), project ID (grant agreement number), project acronym, project status, funding programme, topic, project title, project start date, project end date, project objective, project total cost, EC max contribution (commitment), call ID, funding scheme (type of action), coordinator, coordinator country, participants (ordered in a semi-colon separated list), participant countries (ordered in a semi-colon separated list). The participating organisations are listed in the file 'FP2 Organisations' which includes: project Record Control Number (RCN), project ID, project acronym, organisation role, organisation ID, organisation name, organisation short name, organisation type, participation
DOI: 10.2906/112117098108/17
title: CORDIS - EU research projects under FP4 (1994-1998)

description: This dataset contains all projects funded by the European Union under the fourth framework programme for research and technological development (FP4) from 1994 to 1998. The file 'FP4 Projects' contains the public grant information for each project, including the following information: Record Control Number (RCN), project ID (grant agreement number), project acronym, project status, funding programme, topic, project title, project start date, project end date, project objective, project total cost, EC max contribution (commitment), call ID, funding scheme (type of action), coordinator, coordinator country, participants (ordered in a semi-colon separated list), participant countries (ordered in a semi-colon separated list). The participating organisations are listed in the file 'FP4 Organisations' which includes: project Record Control Number (RCN), project ID, project acronym, organisation role, organisation ID, organisation name, organisation short name, organisation type, participat
DOI: 10.2906/112117098108/18
title: CORDIS - EU funded projects under FP1 (1984–1987)

description: This dataset contains projects funded by the European Union under the first framework programme for research and technological development (FP1) from 1984 to 1987. The file 'FP1 Projects' contains the public grant information for each project, including the following information: Record Control Number (RCN), project ID (grant agreement number), project acronym, project status, funding programme, topic, project title, project start date, project end date, project objective, project total cost, EC max contribution (commitment), call ID, funding scheme (type of action), coordinator, coordinator country, participants (ordered in a semi-colon separated list), participant countries (ordered in a semi-colon separated list). The participating organisations are listed in the file 'FP1 Organisations' which includes: project Record Control Number (RCN), project ID, project acronym, organisation role, organisation ID, organisation name, organisation short name, organisation type, participation e
DOI: 10.2906/112117098108/19
title: Annual Management Report 2020 of the Publications Office
DOI: 10.2906/112117098108/20
title: CORDIS - EU research projects under HORIZON EUROPE (2021-2027)
DOI: 10.34740/kaggle/dsv/4427058
title: YouTube Daily
DOI: 10.26302/sshade/experiment_gm_20221013_001
title: Raman spectra of some tectosilicates